AMAZE 4: once-weekly subcutaneous zenagamtide in adults with overweight or obesity and obstructive sleep apnoea treated with positive airway pressure

Phase 3, randomised, double-blind trial in obesity, Overweight and obstructive sleep apnea hypopnea syndrome (OSAHS) comparing Zenagamtide once weekly with Placebo once weekly (2 arms). Primary endpoints: Relative change in body weight and Change in apnoea-hypopnoea index. Planned start May 2026; status: authorised.